NovoCure (NSDQ:NVCR) shares are under pressure this morning after the company reported second-quarter losses that exceeded estimates.
The British firm’s losses fell -26.7% to -$15.5 million, or -17¢ per share, on sales growth of 60.3% to $61.5 million for the three months ended June 30.
Get the full story at our sister site, Drug Delivery Business News.
The post NovoCure’s Q2 sales top forecast, earnings miss appeared first on MassDevice.
from MassDevice https://ift.tt/2JXimMV
Cap comentari:
Publica un comentari a l'entrada